×
0 0 0 -0.102730819245774 -0.102730819245774 -0.1703511053316 -0.1703511053316 -0.154746423927178
Stock impact report

FDA approves TherapeuticsMD's hormone therapy [Reuters]

TherapeuticsMD, Inc (TXMD)  More Company Research Source: Reuters
NASDAQ:AMEX Investor Relations: ir.therapeuticsmd.com
PDF FDA approves TherapeuticsMD's hormone therapy | Reuters Reuters Staff 1 Min Read (Reuters) - The U.S. Food and Drug Administration approved TherapeuticsMD Inc’s hormone therapy for a painful condition triggered by menopause, the women’s health company said on Wednesday. Its estrogen treatment, Imvexxy, treats vulvar and vaginal atrophy, a condition caused by the loss of female hormone estrogen after menopause. Safety warnings on the drug’s label point to risks of endometrial cancer, cardiovascular disorders, breast cancer, and probable dementia. Reporting by Tamara Mathias in Bengaluru All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays. Š 2018 Reuters. All Rights Reserved. [Read more]
Impact snapshot Event time: TXMD
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last price
VWAP
High:
Max up
High:
Low:
Max down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Opt-in for
TXMD alerts
from News Quantified
Opt-in for
TXMD alerts

from News Quantified
Opt-in for
TXMD alerts

from News Quantified